Europe's regulator is already acting on the oncology upswing
The clearest European data point in this story is a regulatory one. On 24 July 2026 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorization of Gilead's Trodelvy plus Merck's Keytruda in first-line, PD-(L)1-positive metastatic triple-negative breast cancer.1 Gilead said a second first-line approval would establish Trodelvy as a backbone therapy across PD-L1 status in the European Union.1 Evandro de Azambuja said: "People with metastatic triple-negative breast cancer need effective treatment options as early as possible in the course of their disease, particularly when their tumors express PD-L1."1 A CHMP opinion is a recommendation, not a final authorization.
The second European signal is commercial. Novocure, which reports from Baar, Switzerland, posted second-quarter 2026 net revenues of $184 million, up 16% year on year, driven by 18% growth in active patients.2 It received a CE Mark for Optune Pax in locally advanced pancreatic cancer, with Germany the first EU market to launch, and reported more than 280 active patients on Optune Pax as of 30 June 2026.2 Frank Leonard said: "This was our strongest quarter to date, with record net revenues and active patients on therapy."2
The two forces behind the sentiment
Via News's reading of the evidence is that sector optimism rests on two ideas. The first is personalized mRNA cancer vaccines. A vaccine developed by Merck and Moderna stopped melanoma from returning in a clinical trial, according to an event record dated 19 August 2026.3 Moderna and Merck plan to present detailed intismeran results at the ESMO congress on 24 October and to engage with regulators about potential filings.4 That is a scheduled catalyst, not an outcome. Until the detailed data are out, the public record here does not allow us to say how large the benefit is.
The second idea is AI-designed biologics at AstraZeneca. Here the reader should know how thin the footing is. Our main source is an MIT Technology Review article, "How AI helps scientists design the next generation of medicines", in which Puja Sapra describes AstraZeneca's approach.5 In Via News's measured source-reliability check, 0% of 11 checked claims from that document held up.5 We therefore present its content as the company's stated ambition, not as established fact.
With that caveat, the claims are worth reading. Sapra describes a "lab of the future": "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."5 She names data as the differentiator: "Data is our differentiator. We've built an intentionally diverse portfolio across multiple disease areas and drug types."5 She also says automated systems "will generate AI-ready data at a scale that traditional workflows cannot match."5
The same piece is candid about limits. Sapra writes: "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."5 She adds that virtual trials using advanced cell systems and micro-scale organ models could generate "enhanced biological signals without traditional testing bottlenecks", while "human oversight remains at the heart of this approach."5 The dossier contains no clinical result from an AI-designed AstraZeneca biologic. The sentiment is built on a promised shortening of discovery timelines, not on a demonstrated one.
What Merck's verified filings show
Merck is the one company for which we hold checked SEC figures. They show an investment-heavy picture, not a dramatic change of direction. Capital expenditure was $3.863 billion in fiscal 2023, $3.372 billion in 2024 and $4.112 billion in 2025.6 For scale, the 2025 figure is roughly 22 times Novocure's entire quarterly revenue.2,6 Capex rose about 22% in 2025 after falling in 2024. These filings do not say how much of it relates to oncology or mRNA.
Costs have also moved. Cost of revenue was $16.126 billion in 2023, $15.193 billion in 2024 and $16.382 billion in 2025.6 In the second quarter it was $4.395 billion in 2026, against $3.557 billion in 2025, about 24% higher.6 We cannot tell from the filings what drove that rise, and we will not guess.
Cash is the most volatile line. Year-end cash was $6.841 billion (2023), $13.242 billion (2024) and $14.565 billion (2025).6 Quarterly figures swing widely. Cash stood at $18.169 billion in the third quarter of 2025, $5.327 billion in the first quarter of 2026 and $6.849 billion in the second quarter of 2026.6 Large quarter-to-quarter moves in a company's cash balance are not by themselves a warning, and the filings in our dossier do not explain them. The practical point for a retail reader is that Merck is a very large company with sizeable and variable cash. It is not a startup living on a runway.
Smaller companies live on runways and deals
The dossier's contrast is with smaller biotechs. ADC Therapeutics says it "maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations."7 The same weekly roundup headline, however, also reports ADCT cutting jobs.7 A long runway and a reorganization appear side by side.
Treeline Biosciences is taking the transaction route. Standard BioTools says the combined company is expected to have over $900 million at closing.8 Treeline's headline Phase 1 data for TLN-121 in relapsed or refractory lymphomas show an overall response rate of 84% and a complete response rate of 32%, with no observed dose-limiting toxicities.8 Josh Bilenker said: "Strengthening our cash position through this transaction with Standard BioTools will help us accelerate the development of our clinical programs."8 These are early, company-reported results. They are not a regulatory finding.
Telix, listed in Australia and the US, has dosed its first patient in the Phase 3 LUTEON trial of TLX250-Tx for relapsed or recurrent clear cell renal cell carcinoma. It describes this as the first radiopharmaceutical therapy to enter Phase 3 in that cancer.9
How much to trust the sources
The newswire documents here are company announcements, and our measurements of this feed are mixed. Claims checked from the sources behind the Gilead and Novocure documents held up 57% of the time (of 4,954 checked).1,2 The feed behind the Standard BioTools and Telix documents scored 31% (of 2,925).8,9 The roundup feed scored 45% (of 520).7 We treat the Merck SEC numbers, which were fidelity-checked, as the firmest ground, and company-reported clinical figures as claims to be confirmed.
The topic summary also says Q2 guidance was raised at Hematology and Oncology, Opzelura and Kiniksa. The documents in our dossier do not contain those guidance statements, so we cannot verify them here.
What to watch
- 24 October 2026: detailed intismeran data at ESMO, and any signal on regulatory filings.4
- 14 November 2026: the FDA's PDUFA goal date for Summit's ivonescimab application, based on the HARMONi trial.10
- The EU decision on Trodelvy plus Keytruda, following the CHMP opinion of 24 July.1
- Evidence, not intentions, from AI-designed biologics. A clinical result from an AI-designed molecule would test the premise that AstraZeneca's account only describes.5
